CAMK2B(CAMK2b)
Sign in to save this workspaceUniProt Q13554 · PDB · AlphaFold · Substrate: Autocamtide 2 + Ca-CaM · Clone: full lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 98.6% | 1.4% | 91.48 | 0.563 |
| 2 | Brigatinib | 93.5% | 6.5% | 82.96 | 0.513 |
| 3 | Midostaurin | 65.2% | 34.8% | 78.64 | 0.500 |
| 4 | Alectinib | 62.7% | 37.3% | 95.49 | 0.651 |
| 5 | Sunitinib | 60.7% | 39.3% | 91.73 | 0.524 |
| 6 | Ribociclib | 59.0% | 41.0% | 99.25 | 0.729 |
| 7 | Repotrectinib | 56.8% | 43.2% | 84.21 | 0.608 |
| 8 | Pacritinib | 47.5% | 52.5% | 88.64 | 0.452 |
| 9 | Gilteritinib | 46.0% | 54.0% | 88.97 | 0.506 |
| 10 | Baricitinib | 45.3% | 54.7% | 97.99 | 0.616 |
| 11 | Ruxolitinib | 39.5% | 60.5% | 98.25 | 0.592 |
| 12 | Rabusertib | 31.6% | 68.4% | 98.74 | 0.687 |
| 13 | Palbociclib | 23.9% | 76.1% | 98.75 | 0.673 |
| 14 | Ceritinib | 22.2% | 77.8% | 95.44 | 0.618 |
| 15 | Bosutinib | 20.6% | 79.4% | 87.22 | 0.555 |
| 16 | Defactinib | 20.5% | 79.5% | 92.68 | 0.450 |
| 17 | Lorlatinib | 20.3% | 79.7% | 97.24 | 0.694 |
| 18 | Nintedanib | 18.3% | 81.7% | 90.23 | 0.608 |
| 19 | Fedratinib | 16.2% | 83.8% | 96.21 | 0.576 |
| 20 | Axitinib | 13.9% | 86.1% | 93.23 | 0.688 |
Paralog block
CAMK2A, CAMK2B, CAMK2D, CAMK2G
EMT expression
- Mesenchymal log2(TPM+1): 0.45
- Epithelial log2(TPM+1): 0.92
- Fold change: -0.47
- Status: No significant change
High-confidence drugs
- Abemaciclib — inh 98.6% · KISS 35.92
- Brigatinib — inh 93.5% · KISS 24.99
- Ribociclib — inh 59.0% · KISS 16.20
Selectivity landscape vs inhibition on CAMK2B
Each point is one of the 92 approved drugs; color = inhibition % on CAMK2B.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…